100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)

NCT01378104 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

178

Enrollment

OTHER

Sponsor class

Conditions

Sustained Virologic Response
IL28B Polymorphism

Interventions

DRUG: peginterferon alfa 2a (pegasys)
DRUG: peginterferon alfa-2a (pegasys)

Sponsor

The Catholic University of Korea

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]